Francisco Javier Candel, Clínical Microbiology and Infectious Diseases. Transplant Coordination and Cell Tissue Bank. IdISSC and IML Health Research Institutes. Hospital Clínico Universitario San Carlos. Associate Professor. School of Medicine. Complutense University. Madrid. Spain.
Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):9-14. doi: 10.37201/req/s01.03.2023. Epub 2023 Nov 24.
Nosocomial pneumonia is an infection with high clinical impact and high morbimortality in which Pseudomonas aeruginosa plays a priority role, especially in the critically ill patient. Conventional antipseudomonal treatments, historically considered as standard, are currently facing important challenges due to the increase of antimicrobial resistance. In recent years, new antimicrobials have been developed with attractive sensitivity profiles and remarkable efficacy in clinical scenarios of nosocomial pneumonia including bacteremia, mechanical ventilation, infections with multidrug-resistant organisms or situations of therapeutic failure. This new evidence underscores the need to update current clinical guidelines for the antimicrobial treatment of nosocomial pneumonia, especially in the most critically ill patients.
医院获得性肺炎是一种具有高临床影响和高病死率的感染，铜绿假单胞菌在其中起着优先作用，尤其是在重症患者中。传统的抗假单胞菌治疗方法，历史上被认为是标准治疗方法，由于抗菌药物耐药性的增加，目前正面临着重大挑战。近年来，新的抗菌药物已经被开发出来，它们具有有吸引力的敏感性谱和在医院获得性肺炎的临床情况下（包括菌血症、机械通气、耐多药病原体感染或治疗失败的情况）的显著疗效。这一新证据强调了更新当前医院获得性肺炎抗菌治疗临床指南的必要性，特别是在最危重的患者中。
